What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Richard F. Kefford mainly focuses on Melanoma, Internal medicine, Oncology, Cancer research and Surgery.
Richard F. Kefford has included themes like Cancer and Pathology in his Melanoma study.
His research in Clinical trial, Pembrolizumab, Adverse effect, Clinical endpoint and Survival rate are components of Internal medicine.
Richard F. Kefford interconnects Phases of clinical research, V600E, Metastasis, Genotype and Stage in the investigation of issues within Oncology.
His Cancer research research is multidisciplinary, relying on both Protein kinase A, Mutant, Molecular biology, Drug resistance and PTEN.
His studies examine the connections between Surgery and genetics, as well as such issues in Gastroenterology, with regards to Randomized controlled trial and Rash.
His most cited work include:
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (2625 citations)
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations (1946 citations)
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib (1661 citations)
What are the main themes of his work throughout his whole career to date?
Richard F. Kefford mainly investigates Melanoma, Internal medicine, Oncology, Cancer research and Dabrafenib.
His primary area of study in Melanoma is in the field of Vemurafenib.
His Internal medicine research includes elements of Gastroenterology and Surgery.
His work carried out in the field of Oncology brings together such families of science as Metastatic melanoma, Chemotherapy, Hazard ratio, Stage and Ipilimumab.
His Cancer research research incorporates elements of Mutation, Cell cycle, Mutant and MAPK/ERK pathway.
His Dabrafenib study combines topics from a wide range of disciplines, such as Phases of clinical research, Dermatology, Tolerability, Trametinib and Pharmacology.
He most often published in these fields:
- Melanoma (72.46%)
- Internal medicine (58.77%)
- Oncology (45.61%)
What were the highlights of his more recent work (between 2016-2021)?
- Melanoma (72.46%)
- Internal medicine (58.77%)
- Oncology (45.61%)
In recent papers he was focusing on the following fields of study:
Melanoma, Internal medicine, Oncology, Dabrafenib and Trametinib are his primary areas of study.
His Melanoma study results in a more complete grasp of Cancer research.
When carried out as part of a general Internal medicine research project, his work on Clinical trial, Pembrolizumab, Adjuvant and Survival rate is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His studies in Oncology integrate themes in fields like Biomarker, Metastatic melanoma, V600E, Hazard ratio and Stage.
His study in Dabrafenib is interdisciplinary in nature, drawing from both Mutant, Pharmacology and Phases of clinical research.
Richard F. Kefford usually deals with Cancer and limits it to topics linked to Adverse effect and Vemurafenib.
Between 2016 and 2021, his most popular works were:
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma (594 citations)
- Pan-cancer analysis of whole genomes (538 citations)
- Whole-genome landscapes of major melanoma subtypes (514 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His primary areas of study are Melanoma, Internal medicine, Oncology, Cancer and Clinical trial.
To a larger extent, he studies Cancer research with the aim of understanding Melanoma.
Richard F. Kefford has researched Internal medicine in several fields, including Gastroenterology and Surgery.
His Gastroenterology research integrates issues from Survival rate and Randomized controlled trial.
MEK inhibitor is closely connected to Combination therapy in his research, which is encompassed under the umbrella topic of Surgery.
In his study, Stage, Ipilimumab, Pseudoprogression and Progressive disease is strongly linked to Hazard ratio, which falls under the umbrella field of Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
